-
Hengrui Pharma Showcases Global Impact at the 2025 ASCO: 72 Study Results Highlight Chinese Cancer Innovation
The 2025 ASCO Annual Meeting successfully concluded in Chicago on June 3( local time). Hengrui Pharma delivered a strong international presence, featuring 15 innovative drugs and 72 research outcomes. These included 4 oral presentations, 5 rapid oral presentations, 27 poster presentations, and 36 online publications. Multiple groundbreaking research advances has elicited widespread discussion among global…
-
test
document.getElementById(“video”).style.height=document.getElementById(“video”).scr
-
At ASCO25, Prof. Yilong Wu shared key insights on the latest advances in lung cancer treatment.
ASCO25, Prof. Yilong Wu shared key insights on the latest advances in lung cancer treatment.
-
Prof. Olaf Penack: Standardized GVHD Management in Europe and Future Strategies | 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy
Editor’s Note: The 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy was recently held successfully in Guangzhou. The conference was co-hosted by the Hematology Branch of…
-
Prof. Anna Sureda, President of EBMT, on China-Europe Collaboration and the Future of Cellular Therapy | 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy
Editor’s Note:The 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy was recently held successfully in Guangzhou. The conference was co-hosted by the Hematology Branch of the…
-
Professor Shun Lu: High Efficacy and Low Toxicity—SHR-A1811 Opens a New Era of ADC Therapy for HER2-Mutant NSCLC
At the 2025 Annual Meeting of the American Association for Cancer Research (AACR), the China-developed HER2-directed antibody-drug conjugate (ADC) Trastuzumab rezetecan(SHR-A1811) made a striking appearance with new data from the HORIZON-Lung study: an objective response rate (ORR) of 74.5%, a median progression-free survival (PFS) of 11.5 months, and an interstitial lung disease (ILD) incidence of…
Connecting Medical Expertise through Media